Virtual Reality-Based Dichoptic Therapy for Childhood Amblyopia: A Narrative Review

Abstract

Background: Amblyopia commonly referred to as 'lazy eye' affects an estimated 1%–5% of children worldwide, making it the most prevalent cause of preventable monocular visual impairment in the pediatric population. Conventional treatments, including occlusion therapy (patching) and atropine penalization, improve monocular visual acuity (VA) by suppressing input from the fellow eye; however, they are beset by poor patient adherence, psychological burden, and the persistent failure to rehabilitate binocular visual function and stereoacuity.

Methods: A comprehensive narrative review was performed using systematic searches of PubMed, Embase, the Cochrane Library, and Web of Science, covering peer-reviewed publications from 2020 to 2026. Search terms included amblyopia, dichoptic therapy, virtual reality, binocular treatment, lazy eye, VR headset, Luminopia, and CureSight. Randomized controlled trials (RCTs), systematic reviews, meta-analyses, pilot studies, and prospective cohort studies evaluating VR-based dichoptic interventions in children with amblyopia were included.

Results: The evidence base encompasses two U.S. Food and Drug Administration (FDA)-cleared dichoptic devices Luminopia (VR headset) and CureSight (eye-tracking-based dichoptic system) alongside multiple investigational platforms. Pivotal RCTs demonstrated non-inferiority of dichoptic VR therapy to conventional patching in improving amblyopic eye VA, with improvements ranging from 0.28 to 1.32 logMAR lines over 10–16 weeks. Dichoptic VR therapy conferred superior stereoacuity outcomes, with significant reductions in stereoscopic thresholds compared with monocular suppression-based approaches. Treatment adherence exceeded 80%–91% in multiple studies, substantially surpassing patching compliance rates. Adverse events were predominantly mild and transient, including cybersickness and temporary diplopia. Systematic reviews and meta-analyses confirm the overall efficacy of dichoptic therapy as a non-inferior to equivalent alternative to patching, with a statistically significant small advantage over patching reported in the most recent meta-analysis (mean difference 0.02 logMAR; 95% CI: 0.00–0.04).

Conclusions: VR-based dichoptic therapy constitutes a scientifically grounded, patient-centered, and increasingly evidence-supported treatment paradigm for childhood amblyopia. Its capacity to simultaneously improve VA, stereo acuity, and binocular function while offering superior adherence and reduced psychosocial burden positions it as a compelling alternative or adjunct to conventional therapy. Future research priorities include standardized treatment protocols, long-term durability data, integration of adaptive artificial intelligence algorithms, and comparative effectiveness studies across amblyopia subtypes and age groups.